The Ultimate Directory on Healthcare Webinars

We are excited to invite you to our upcoming webinar, "Glaucoma Medications: From Drops to Implants," featuring Arpine Barsegian, MD. This informative session will delve into the latest advancements in glaucoma treatments, covering a comprehensive range of medication options from traditional eye drops to innovative implant technologies.Speakers: Michelle de Elizalde (Assistant Director of Patient and Research Programs) and Arpine Barsegian, MD (Ophthalmologist)

Monoclonal antibodies represent a highly successful class of therapeutics that are used to treat complex diseases across a wide range of therapeutic areas. However, their high cost and variable patient response underscores the need for new modalities that can be used to activate or suppress the immune system. Aptamers have long been viewed as a simpler alternative to antibodies, but challenges with biostability, effectiveness, and throughput have slowed their progress in the clinic. In this talk, I will discuss a path for democratizing antibody therapeutics that relies a class of molecules called threomers, which are highly functionalized synthetic nucleic acids assembled on a biologically stable threose nucleic acid (TNA) framework. I will describe the underlying chemistry and enzyme engineering developed to support a high throughput discovery pipeline and provide examples of recently discovered threomers that mirror the binding properties of antibodies.Speaker: John Chaput, PhD, Professor - University of California, Irvine

Learner Outcomes: By the end of this webinar, attendees should be able to articulate why it’s important to consider a patient community audience when planning scientific and data dissemination including incorporating their voice within it. They will also gain confidence to follow clear methodologies to incorporate the patient voice within publications and understand the role of Medical Affairs in disease awareness campaigns. Additionally, participants will learn best practice approaches including novel ways to disseminate information.Speakers: Tracy Hart (CEO, Osteogenesis Imperfecta foundation) and Gavin Jones (Global Healthcare Agency Lead, Lumanity).

Losing a partner is a life-changing experience. We draw on numerous datasets to examine differences between widowed and partnered older women and to provide a comprehensive picture of well-being in widowhood. Most importantly, our analysis accounts for time use in widowhood, an aspect which has not been studied previously. Based on data from several European countries we trace the evolution of well-being of women who become widowed by comparing them with their matched non-widowed ‘statistical twins’ and examine the role of an exceptionally broad set of potential moderators of widowhood’s impact on well-being. We confirm a dramatic decrease in mental health and life satisfaction after the loss of a partner, followed by a slow recovery. An extensive set of controls recorded prior to widowhood, including detailed family ties and social networks, provides little help in explaining the deterioration in well-being. Unique data from time-diaries kept by older women from several European countries and the U.S. tell us why: the key factor behind widows’ reduced well-being is increased time spent alone.Presented by Dr. Michal Myck, Director, Centre for Economic Analysis, CenEA.

In preparation for the introduction of the new Aged Care Act and strengthened Quality Standards, this webinar will introduce the Commission’s new draft Regulatory Strategy that describes how we will deliver on our commitment to safeguard and protect older people, and how we hold providers and workers to account. It will advise providers and workers what we expect from them, and how we will engage with them. Importantly, it also tells older people and their families, as well as providers and workers what they can expect from us.SpeakersJanet Anderson, PSM, Aged Care Quality and Safety CommissionerLisa Peterson, PSM, Deputy Commissioner, Sector Capability and Regulatory Strategy, Aged Care Quality and Safety CommissionLouise Macleod, Complaints Commissioner, Aged Care Quality and Safety CommissionPeter Edwards, Executive Director, Compliance Management Group, Aged Care Quality and Safety CommissionEmma Jobson, Executive Director, Regulatory Policy and Intelligence, Aged Care Quality and Safety CommissionAnthony Speed, Executive Director, Quality Assessment and Monitoring, Aged Care Quality and Safety Commission

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.KEY TOPICS:- Development pathway for new medicines- Proof of concept- Phase 2 clinical development- Running not-for-profit programs- Partnering with pharmaceuticalsSPEAKER:Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash UniversityABOUT PETE LAMBERT:Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.

Join us for an insightful webinar where we will delve into the comprehensive vision of the ODIN project. This session will provide an in-depth look at the strategies developed to effectively integrate change management practices in hospital settings, alongside the barriers and challenges faced when introducing innovations into hospital processes.Key Details:Date: 10th JulyTime: Between 12pm and 1pm CET (60 minutes max)Presenter: MSc. Beatriz MerinoPresenter Profile: MSc. Beatriz Merino is a Biomedical Engineer specializing in Medical Images, with credentials from the Technical University of Madrid. She holds a Master’s in Biomedical Engineering with a focus on management and innovation in healthcare technologies, as well as a Master of Business Administration. Since 2017, she has been a researcher and project manager at the Life Supporting Technologies (LifeSTech) research group. Her research focuses on ICT in the Health domain and active and healthy aging, particularly chronic disease management and diabetes.Webinar Highlights:Detailed exploration of the ODIN project’s vision.Insights into the development and integration of change management practices in hospitals.Discussion of the barriers and challenges in implementing innovations in hospital processes.Don’t miss this opportunity to gain valuable knowledge and perspectives on managing change and innovation within the healthcare sector.

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis (EAA), is an immune-mediated interstitial lung disease triggered by inhaled antigens such as molds, bird feathers, and agricultural dusts. Often linked to working conditions, HP is a disease of many faces, from inflammatory self-limiting disease to relapsing or progressive inflammatory disease and chronic fibrotic disease. As there does not exist a single, universal diagnostic criterion, HP is diagnosed by a combination of findings established through clinical history, including imaging, histopathology, pulmonary function testing, bronchoscopy, and serology. With the rise of automated immunoassays capable of quantitatively measuring specific IgG to common HP antigens, an expanded diagnostic can be used to detect the potential triggering antigen.This webinar delves into the pathophysiology of HP, highlights the diagnostic criteria according to the current guidelines, and emphasizes the utility of specific IgG determination and the importance of cutoff values in HP.Key learning objectives:Describe the pathophysiology of hypersensitivity pneumonitisExplain the diagnostic criteria used to establish HPDiscuss the value of serology in HPAccreditation statementSelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.Presenters: Dora Wells (Editorial Team, SelectScience) and Dr. Johannes Grosch (Clinical Expert, Siemens Healthineers).

Skin, Healing and Immune Response Chairperson Prof. Andrea R. Genazzani. Speakers: Prof. Frederick Naftolin Estrogens and Skin Prof. Mark Brincat The effects of Hormonal Contraception including COC, And HRT on Collagen turnover.

Join our expert speakers as we discuss birth trauma; the definition, the impacts on physical and mental health, and how to get help.Birth trauma has been hitting the headlines, with thousands of women coming forward to describe the debilitating psychological, physical, and societal impacts of traumatic births on their lives. 30,000 women develop post-traumatic stress disorder (PTSD) every year because of a frightening, stressful or distressing events related to childbirth. Many also find themselves recovering from birth injuries which can be life altering, resulting in chronic pain, incontinence and infertility.Join our expert speakers as we explore this subject in more detail, answering the key questions; What are the main causes of birth trauma? What are the psychological and physical impacts? And most importantly, what support is available for the people affected?Have a question for one of our speakers? Email [email protected] before the event and they’ll do their best to answer your questions during the session.